EYLEA®

Looking to buy EYLEA® online for your practice? The sales representatives at Med Supply Solutions can give you all the information you need. EYLEA® is also used for diabetic eye disease and other conditions of the retina. It impedes the expansion and leakage of fluid from irregular blood vessels situated at the rear of the eye, which can affect vision. Support your patients affected with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Unlock a World of Possibilities by Signing Up.If our initial offerings haven't caught your eye, there's more we can do. Register for specialized product consultations aimed at exploring the full potential of your clinic's services.

What Is EYLEA® Used For?

Aflibercept, sold under the brand name EYLEA® is used for treating diseases such as Macular Degeneration, Diabetic Retinopathy and Macular Edema. Functioning as a vascular endothelial growth factor inhibitor, it serves to curb angiogenesis. Buy EYLEA® for your patients since it is the only approved anti-VEGF to successfully extend to 16-week treatment intervals in clinical trials with a T&E dosing regimen.

EYLEA® Indications: Which Conditions Does EYLEA® Address?

EYLEA® is FDA-approved and prescribed for the following eye conditions:

Wet age-related macular degeneration (AMD)
Retinal swelling, known as macular edema
Diabetic retinopathy
Retinal vein occlusion
Choroidal neovascularization (the growth of small, abnormal blood vessels beneath the retina, potentially causing vision loss)

How Does EYLEA® Work?

EYLEA® operates by building upon the inhibition of VEGF-A to achieve a more potent blockade of the VEGFR-1/2 system. Its mechanism involves targeting and binding to VEGF-A with heightened affinity, effectively neutralizing its activity. By doing so, EYLEA® diminishes the activation of both VEGFR-1 and VEGFR-2, crucial receptors involved in angiogenesis and vascular permeability regulation. It incorporates a multi-targeted trap that not only blocks VEGF-A but also intercepts all VEGFR-1 ligands, including the placental growth factor (PGF).

EYLEA® Injection Preparation

EYLEA® is for intravitreal injection only. Each 1 mL solution for injection contains 40 milligrams of aflibercept*. A single pre-filled syringe holds an extractable volume of at least 0.09 mL, corresponding to a minimum of 3.6 mg of aflibercept. This quantity is sufficient to administer a single dose of 0.05 mL, containing 2 mg of aflibercept. The EYLEA® pre-filled syringe (PFS) is meant for single use only, and any leftover product should be discarded after injection to prevent contamination and potential infection. Before administering the injection, visually inspect the solution to ensure it is clear and free of any particles or discoloration. The unopened blister pack can be stored at room temperature for up to 24 hours, but once opened, it should be handled under aseptic conditions. For intravitreal injection, use a 30 G x ½ inch injection needle.

EYLEA® Administration

After preparation, using an aseptic technique, carefully remove the syringe from the sterilized blister pack. Hold the syringe with one hand and use your other hand to twist off (do not snap off) the syringe cap, ensuring sterility is maintained. Avoid pulling back on the plunger to prevent compromising the product's sterility. Next, with the needle pointing up, firmly twist the injection needle onto the Luerlock syringe tip. Check the syringe for bubbles by holding it with the needle pointing up; if bubbles are present, gently tap the syringe until they rise to the top. To remove all bubbles and expel excess drug, slowly depress the plunger rod until the cylindrical base of the plunger dome edge aligns with the black dosing line on the syringe, equivalent to 50 microliters. EYLEA® intravitreal injection must only be administered by a qualified physician. The recommended dose is 2 mg (0.05 mL or 50 microliters) administered every four weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL) once every eight weeks (2 months).

EYLEA® Side Effects and Precautionary Measures

Special precaution is needed in patients with poorly controlled glaucoma (do not inject EYLEA® while the intraocular pressure is ≥ 30 mmHg). Reports indicate that systemic adverse events, such as non-ocular hemorrhages and arterial thromboembolic events, have been documented after intravitreal injection of VEGF inhibitors. It is hypothesized that these occurrences may be linked to VEGF inhibition. Safety data concerning the treatment of patients with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular edema (DME), or myopic choroidal neovascularization (CNV) who have experienced a stroke, transient ischemic attacks, or myocardial infarction within the last six months are limited. Therefore, caution is advised when administering treatment to such patients.

EYLEA® vs. Competition

The conducted studies demonstrate comparable efficacy between EYLEA® and ranibizumab in preserving and improving visual acuity over 52 and 96 weeks, with slight variations observed in the mean number of injections and the proportion of patients experiencing visual acuity gain.

Where Can I Buy EYLEA® Online?

If you have an inquiry and would like to order EYLEA® online, feel free to contact our team for assistance. Our dedicated sales agents are available to provide information on how to buy EYLEA® wholesale.

Products

Cart